The overall objective of this grant is the development of multidisciplinary approaches to the staging and surgical treatment of clinically localized melanoma and other solid neoplasms. Accurate molecular, immunologic and pathologic assessment of the primary tumor, the regional lymphatic drainage basin, and the blood will be used to identify candidates for postoperative adjuvant therapy and differentiate these patients from those in whom surgical therapy alone is curative. During the prior periods, we developed and applied intraoperative lymphatic mapping and sentinel lymph node dissection (LM/SLND) for identification of occult nodal metastasis from a primary cutaneous melanoma. The accuracy and reproducibility of LM/SLND used in our multicenter trial (MSLT-I) has been validated, and the MSLT-I has completed accrual of 2001 patients. Because most patients with tumor-positive sentinel nodes have no further nodal involvement, we hypothesize that LM/SLND may be all the nodal surgery that is necessary if sentinel node metastases are micrometastatic, i.e., identified only by immunohistochemical and/or molecular assessment. We will investigate this hypothesis in a new multicenter trial (MSLT-II): all patients will undergo LM/SLND, and those with SN micrometastases will be randomized to complete nodal dissection or routine follow up plus ultrasonography (0001). Nodal tissue will be evaluated by quantitative multimarker reverse transcriptase-polymerase chain reaction (0003) and by morphometric assessment (0005). Blood specimens will be evaluated for immunologic markers of the endogenous response to disease (0001) and genetic markers of tumor cells (0003). All of these investigations will improve our ability to determine the presence and extent of subclinical metastasis from a primary cutaneous melanoma, to stratify patients for postsurgical adjuvant trials, and to optimize the quality of life and reduce the cost of postoperative follow-up care for patients who are cured by surgery alone.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA029605-26
Application #
7273726
Study Section
Subcommittee G - Education (NCI)
Program Officer
Xie, Heng
Project Start
1981-04-01
Project End
2009-05-31
Budget Start
2007-07-18
Budget End
2008-05-31
Support Year
26
Fiscal Year
2007
Total Cost
$6,468,908
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Jones, Maris S; Lee, Jihey; Stern, Stacey L et al. (2017) Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 225:149-158
Faries, Mark B; Thompson, John F; Cochran, Alistair J et al. (2017) Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 376:2211-2222
Ozao-Choy, Junko; Nelson, Daniel W; Hiles, Jason et al. (2017) The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol 116:337-343
Karakousis, Giorgos; Gimotty, Phyllis A; Bartlett, Edmund K et al. (2017) Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol 24:952-959
Jones, Maris S; Torisu-Itakura, Hitoe; Flaherty, Devin C et al. (2016) Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 82:1009-1013
Faries, Mark B (2016) Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog 21:65-73
Deutsch, Gary B; Kirchoff, Daniel D; Faries, Mark B (2015) Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am 24:279-98
Marzese, Diego M; Hoon, Dave Sb (2015) Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 15:647-64
Marzese, Diego M; Liu, Michelle; Huynh, Jamie L et al. (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28:82-93
Wang, Jinhua; Hua, Wei; Huang, Sharon K et al. (2015) RASSF8 regulates progression of cutaneous melanoma through nuclear factor-?b. Oncotarget 6:30165-77

Showing the most recent 10 out of 256 publications